Efficacy of front-line ceritinib vs chemotherapy
according to presence of brain metastases at baseline
de Castro, et al. WCLC 2016 (Abs. PL03.07)
8.3
26.3
0
PFS estimate
1.0
0.8
0.6
0.4
0.2
0
Time (months)
6.7
10.7
1.0
0.8
0.6
0.4
0.2
0
HR = 0.70 (0.44–1.12)
Ceritinib (n=59)
Chemotherapy (n=62)
Ceritinib (n=130)
Chemotherapy (n=125)
HR = 0.48 (0.33–0.69)
33
30
27
24
21
18
15
12
9
6
3
Time (months)
Patients with no brain metastases at baseline
0
33
30
27
24
21
18
15
12
9
6
3
Patients with brain metastases at baseline
INDICACIÓN PENDIENTE DE APROBACIÓN,
